Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers

Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers is a phase 3, randomised interventional study registered as NCT05194878 by Sun Yat-sen University, with a registry enrolment figure of 840 participants, started 2021-12-01 and due to reach its primary completion in 2024-12. Interventions recorded: neoadjuvant chemotherapyI; Colectomy; adjuvant chemotherapy. Conditions listed: Colon Cancer Stage II; Colon Cancer Stage III. Primary outcome: Disease-free survival. Colorectal eligibility wording from the registry: "* Histologically proven adenocarcinoma or high grade dysplasia on histology plus unequivocal radiological evidence of invasive cancer of the colon(≥ 12 cm from the anal verge)". Sites: China. No results are recorded here; the registry entry is the source.